

Special Issue

Advances in the Research and Treatment of Pancreatic Cancer

Message from the Guest Editor

Pancreatic cancer is one of the most lethal malignant tumors and its incidence is on the rise. Over the past decades, there has been very little progress in the development of novel and effective drugs. More recently, new treatment options such as minimally invasive surgery, the selection of appropriate patients for neoadjuvant treatment and aggressive surgery, and promising chemotherapy options have been added to the treatment armamentarium. Yet, despite these advances, pancreatic cancer remains an incurable disease for the majority of patients. The focus of this Special Issue is on recent advances in research and treatment that are helping to make pancreatic cancer a potentially curable disease.

Guest Editor

Dr. Fabio Ausania

Department of Surgery, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain

Deadline for manuscript submissions

closed (18 April 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/207737

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)